Cara expects to end 2023 with approximately $100 million in cash. This amount includes the $17.5 million already received from HealthCare Royalty, less certain expenses, and the first milestone payment of $20 million, which was triggered by the achievement of the milestone this month and is expected to be received by year-end 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CARA:
- Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
- Cara shares ‘highly disconnected’ from DFK potential, says H.C. Wainwright
- Cara Therapeutics price target lowered to $11 from $23 at Canaccord
- Cara Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Cara closes financing transaction with HealthCare Royalty extending cash runway
